As respiratory syncytial virus (RSV), a seasonal pathogen in young children is challenging the national health care system as part of an unprecedented 鈥渢ripledemic鈥� with COVID-19 and flu this winter, 量子资源网 authors weigh in on potential coverage pathways for new monoclonal antibody (mAb) preventive therapies for RSV and their implications for access.
The Vaccines for Children (VFC) program is a proven vehicle for聽ensuring聽comprehensive coverage of immunizations based on recommendations from the Advisory Committee on Immunization Practices (ACIP).聽An ACIP聽workgroup聽is actively discussing potential recommendations for immunization with RSV mAbs.聽
In the recent Health Affairs Forefront article, “,” 量子资源网 authors Helen DuPlessis, MD, FAAP, Diana Rodin, and Matt Wimmer explore the implications of ACIP recommendations, Medicaid coverage pathways, and children鈥檚 access to the new therapies.
